Titan Pharmaceuticals, Inc. (TTNP) Financials

$3.24

north_east
$0.02 (0.62%)
Day's range
$3.16
Day's range
$3.34

TTNP Income statement / Annual

Last year (2023), Titan Pharmaceuticals, Inc.'s total revenue was $184,000.00, an increase of 206.67% from the previous year. In 2023, Titan Pharmaceuticals, Inc.'s net income was -$5.57 M. See Titan Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Operating Revenue $184,000.00 $60,000.00 $1.53 M $4.84 M $3.61 M $5.91 M $215,000.00 $15.07 M $1.67 M $3.65 M
Cost of Revenue $112,000.00 $196,000.00 $199,000.00 $472,000.00 $1.29 M $538,000.00 $9.65 M $6.13 M $4.68 M $4.08 M
Gross Profit $72,000.00 -$136,000.00 $1.33 M $4.37 M $2.32 M $5.37 M -$9.43 M $8.94 M -$3.00 M -$429,000.00
Gross Profit Ratio 0.39 -2.27 0.87 0.9 0.64 0.91 -43.87 0.59 -1.8 -0.12
Research and Development Expenses $1.91 M $4.76 M $5.69 M $5.92 M $7.24 M $7.48 M $9.65 M $6.13 M $4.68 M $4.08 M
General & Administrative Expenses $5.55 M $6.03 M $4.99 M $5.80 M $5.40 M $0.00 $5.07 M $4.60 M $3.76 M $3.05 M
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $6.52 M $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $5.55 M $6.03 M $4.99 M $5.80 M $11.93 M $6.87 M $5.07 M $4.60 M $3.76 M $3.05 M
Other Expenses -$183,000.00 -$497,000.00 -$84,000.00 $1.72 M $17,000.00 -$6,000.00 -$55,000.00 $0.00 $0.00 $0.00
Operating Expenses $7.28 M $10.30 M $10.68 M $11.72 M $19.17 M $13.64 M $14.72 M $10.72 M $8.43 M $7.12 M
Cost And Expenses $7.46 M $10.30 M $10.88 M $12.19 M $20.46 M $14.18 M $14.72 M $10.72 M $8.43 M $7.12 M
Interest Income $5,000.00 $53,000.00 $1,000.00 $769,000.00 $967,000.00 $0.00 $0.00 $0.00 $0.00 $0.00
Interest Expense $0.00 $0.00 $1,000.00 $769,000.00 $967,000.00 $887,000.00 $369,000.00 $37,000.00 $0.00 $0.00
Depreciation & Amortization $112,000.00 $196,000.00 $221,000.00 $292,000.00 $244,000.00 $380,000.00 $417,000.00 $377,000.00 $358,000.00 $353,000.00
EBITDA -$7.17 M -$10.04 M -$9.13 M -$7.06 M -$6.28 M -$7.88 M -$14.09 M $4.72 M -$6.40 M -$3.12 M
EBITDA Ratio -38.94 -167.32 -6.42 -1.1 -4.97 -1.36 -68.39 0.26 -1.13 -1.15
Operating Income Ratio -39.55 -170.58 -6.13 -1.52 -4.66 -1.4 -67.45 0.29 -4.04 -0.95
Total Other Income/Expenses Net $1.71 M $29,000.00 $578,000.00 -$56,000.00 $386,000.00 -$759,000.00 $195,000.00 $792,000.00 -$4.52 M $1.07 M
Income Before Tax -$5.57 M -$10.21 M -$8.78 M -$7.41 M -$16.46 M -$9.02 M -$14.31 M $5.14 M -$11.28 M -$2.40 M
Income Before Tax Ratio -30.27 -170.1 -5.75 -1.53 -4.56 -1.53 -66.54 0.34 -6.75 -0.66
Income Tax Expense $0.00 -$29,000.00 -$662,000.00 $13.32 M -$369,000.00 -$1.65 M -$250,000.00 -$792,000.00 $4.52 M -$1.07 M
Net Income -$5.57 M -$10.18 M -$8.11 M -$20.73 M -$16.09 M -$9.02 M -$14.31 M $5.14 M -$11.28 M -$2.40 M
Net Income Ratio -30.27 -169.62 -5.32 -4.28 -4.46 -1.53 -66.54 0.34 -6.75 -0.66
EPS -7.41 -15.15 -16.68 -109.88 -12602.35 -47.59 -121.48 44.71 -101.24 -25.36
EPS Diluted -7.41 -15.15 -16.68 -109.88 -12602.35 -47.59 -121.34 36.01 -101.24 -25.35
Weighted Average Shares Out $752,000.00 $671,700.00 $486,500.00 $188,650.00 $1,276.67 $189,598.00 $117,775.00 $115,209.00 $111,404.00 $94,760.00
Weighted Average Shares Out Diluted $752,000.00 $671,700.00 $486,500.00 $188,650.00 $1,276.67 $189,598.00 $117,908.00 $119,208.00 $111,404.00 $94,777.00
Link